321 related articles for article (PubMed ID: 23390298)
1. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.
Quinn KM; Da Costa A; Yamamoto A; Berry D; Lindsay RW; Darrah PA; Wang L; Cheng C; Kong WP; Gall JG; Nicosia A; Folgori A; Colloca S; Cortese R; Gostick E; Price DA; Gomez CE; Esteban M; Wyatt LS; Moss B; Morgan C; Roederer M; Bailer RT; Nabel GJ; Koup RA; Seder RA
J Immunol; 2013 Mar; 190(6):2720-35. PubMed ID: 23390298
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
[TBL] [Abstract][Full Text] [Related]
3. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.
Tan WG; Jin HT; West EE; Penaloza-MacMaster P; Wieland A; Zilliox MJ; McElrath MJ; Barouch DH; Ahmed R
J Virol; 2013 Feb; 87(3):1359-72. PubMed ID: 23175355
[TBL] [Abstract][Full Text] [Related]
5. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
[TBL] [Abstract][Full Text] [Related]
6. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.
Koup RA; Roederer M; Lamoreaux L; Fischer J; Novik L; Nason MC; Larkin BD; Enama ME; Ledgerwood JE; Bailer RT; Mascola JR; Nabel GJ; Graham BS; ;
PLoS One; 2010 Feb; 5(2):e9015. PubMed ID: 20126394
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.
Martins MA; Bonaldo MC; Rudersdorf RA; Piaskowski SM; Rakasz EG; Weisgrau KL; Furlott JR; Eernisse CM; Veloso de Santana MG; Hidalgo B; Friedrich TC; Chiuchiolo MJ; Parks CL; Wilson NA; Allison DB; Galler R; Watkins DI
PLoS One; 2013; 8(1):e54434. PubMed ID: 23336000
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
[TBL] [Abstract][Full Text] [Related]
9. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.
Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH
J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575
[TBL] [Abstract][Full Text] [Related]
10. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
[TBL] [Abstract][Full Text] [Related]
11. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
12. Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development.
Cheng C; Wang L; Ko SY; Kong WP; Schmidt SD; Gall JGD; Colloca S; Seder RA; Mascola JR; Nabel GJ
Vaccine; 2015 Dec; 33(51):7344-7351. PubMed ID: 26514419
[TBL] [Abstract][Full Text] [Related]
13. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
14. Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag.
Haut LH; Lin SW; Tatsis N; DiMenna LJ; Giles-Davis W; Pinto AR; Ertl HC
Eur J Immunol; 2010 Dec; 40(12):3426-38. PubMed ID: 21108465
[TBL] [Abstract][Full Text] [Related]
15. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
[TBL] [Abstract][Full Text] [Related]
16. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
18. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.
Quinn KM; Zak DE; Costa A; Yamamoto A; Kastenmuller K; Hill BJ; Lynn GM; Darrah PA; Lindsay RW; Wang L; Cheng C; Nicosia A; Folgori A; Colloca S; Cortese R; Gostick E; Price DA; Gall JG; Roederer M; Aderem A; Seder RA
J Clin Invest; 2015 Mar; 125(3):1129-46. PubMed ID: 25642773
[TBL] [Abstract][Full Text] [Related]
19. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
[TBL] [Abstract][Full Text] [Related]
20. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
